NTrans Technologies closes Series A investment to accelerate development of gene editing therapy
We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations.
